Literature DB >> 20026653

The p38 MAPK family, a pushmi-pullyu of skeletal muscle differentiation.

Andrew B Lassar1.   

Abstract

In this issue, Gillespie et al. (Gillespie et al. 2009. J. Cell Biol. doi:10.1083/jcb.200907037) demonstrate that the mitogen-activated protein kinase isoform p38-gamma plays a crucial role in blocking the premature differentiation of satellite cells, a skeletal muscle stem cell population. p38-gamma puts the brakes on skeletal muscle differentiation by promoting the association of the transcription factor MyoD with the histone methyltransferase, KMT1A, which act together in a complex to repress the premature expression of the gene encoding the myogenic transcription factor Myogenin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20026653      PMCID: PMC2806286          DOI: 10.1083/jcb.200911123

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


Satellite cells are myogenic progenitors that reside between the sarcolemma and basal lamina of the muscle fiber and play a crucial role in postnatal muscle growth and regeneration (for review see Zammit et al., 2006a). During skeletal muscle regeneration, these quiescent muscle precursor cells are “activated” to enter the cell cycle, and give rise to a transient amplifying population of skeletal muscle progenitor cells termed myoblasts. Although quiescent satellite cells express the transcription factor Pax7 (Seale et al., 2000), activated satellite cells express the myogenic transcription factor MyoD (Zammit et al., 2006b). Activated satellite cells face a very important developmental decision to either continue to divide or differentiate into skeletal muscle cells that fuse with existing myofibers. Among the various signaling pathways thought to control this important decision, the p38 mitogen-activated protein kinase (MAPK) family stands out as being crucial. p38 MAPK activity has been known for several years to be necessary to promote skeletal muscle differentiation (Zetser et al., 1999). Indeed, mice lacking p38-α MAPK display delayed myofiber growth and maturation in vivo, and proliferating skeletal muscle cells isolated from such mice display defective differentiation in vitro (Perdiguero et al., 2007). p38-α MAPK activity has been demonstrated to promote skeletal muscle differentiation by (a) enhancing dimerization of myogenic regulatory factors with their E protein binding partners (Lluís et al., 2005), (b) recruiting the SWI-SNF complex to skeletal muscle differentiation genes (Simone et al., 2004), and (c) activating the transcriptional activity of MEF2, which works in a positive feed-forward loop with MyoD to promote differentiation (Penn et al., 2004). In this issue, Gillespie et al. demonstrate that a different p38 MAPK family member, p38-γ, also plays a crucial role in regulating skeletal muscle differentiation. Interestingly (and surprisingly), this study indicates that p38-γ MAPK does not promote skeletal muscle differentiation but instead acts to block the premature induction of this program in activated satellite cells. Since the discovery of MyoD (Davis et al., 1987), one of a family of muscle regulatory factors that both induce and coordinate the skeletal muscle differentiation program (for review see Tapscott, 2005), it has been apparent that the transcriptional activity of these basic helix-loop-helix (bHLH) transcription factors must be tightly regulated. Although MyoD is expressed in proliferating myoblasts, the skeletal muscle differentiation program is only induced in these cells after mitogen withdrawal. One of the first differentiation-specific transcriptional targets to be induced by MyoD is another muscle regulatory factor, termed Myogenin (Hollenberg et al., 1993), whose expression is essential to execute the differentiation program (Hasty et al., 1993; Nabeshima et al., 1993). The signals and transcriptional regulatory machinery that restrict Myogenin expression to differentiating myocytes has been an area of intense scrutiny during the past decade. Myogenin is a direct transcriptional target of MyoD (Hollenberg et al., 1993), and the myogenin promoter contains both a high-affinity MyoD binding site (a canonical E box) and a low-affinity MyoD binding site (a noncanonical E box), the latter of which is located adjacent to a homeodomain binding site (Berkes et al., 2004). Interaction between MyoD and the homeodomain protein Pbx has been demonstrated to stabilize binding of MyoD to this low-affinity binding site (Berkes et al., 2004). What factors inhibit the inappropriate induction of myogenin in proliferating myoblasts? Early studies by Benezra et al. (1990) documented that expression of Id1—a dominant-negative HLH protein that competes with MyoD for interaction with its obligate DNA-binding partners, the bHLH E proteins—is down-regulated during skeletal muscle differentiation; this observation led to the hypothesis that members of the Id protein family might act to restrict MyoD activity in proliferating myoblasts by blocking interaction of MyoD with DNA (Benezra et al., 1990). However, because chromatin immunoprecipitation assays have more recently demonstrated that MyoD is indeed bound to various transcriptional targets, including Myogenin, in proliferating myoblasts (Mal and Harter, 2003; Blais et al., 2005; Ishibashi et al., 2005; Ohkawa et al., 2006), there must be a non–Id-based mechanism for restricting Myogenin expression to differentiated cells. An initial clue to resolve this issue was the identification of the histone modification mark H3K9me3 over the myogenin promoter specifically in proliferating myoblasts (Mal and Harter, 2003). This histone modification is associated with facultative heterochromatin and is “read” by the transcriptional corepressor HP1, which in turn can interact with other heterochromatin-associated proteins (for review see Lomberk et al., 2006). Importantly, Mal demonstrated that MyoD could be isolated in complex with the histone methyl-transferase KMT1A (also known as Suv39h1), the “writer” of H3K9me3 modification, specifically in proliferating myoblasts but not in differentiated myocytes (Mal, 2006). This important observation suggested that differential interaction of MyoD with KMT1A in proliferating myoblasts versus differentiated myocytes may act to restrict transcriptional activation of target genes by MyoD to the latter. What signals modulate interaction of MyoD with KMT1A differentially in myoblasts versus differentiated myocytes? Gillespie et al. (2009) demonstrate that p38-γ MAPK phosphorylates the carboxy terminus of MyoD on serines 199 and 200, leading to increased interaction of MyoD with KMT1A. Consistent with these observations, this study also demonstrates that satellite cell–derived myoblasts isolated from mice lacking p38-γ MAPK display decreased KMT1A association with chromatin encompassing the myogenin promoter, and consequently display both accelerated expression of Myogenin and decreased proliferation in vitro. Most importantly, satellite cells in p38-γ–null mice display increased expression of Myogenin, loss of Pax7 expression, and markedly defective skeletal muscle differentiation in vivo (Gillespie et al., 2009). Surprisingly, another group did not observe either regeneration defects in p38-γ–null mice or altered differentiation of myoblasts derived from these animals (Ruiz-Bonilla et al., 2008), which suggests that mouse strain–specific genetic modifiers may alter the response of myoblasts to p38-γ deficiency. The consistent set of observations of Gillespie et al. (2009) make a compelling argument that p38-γ MAPK plays a crucial role in blocking the premature induction of Myogenin and consequent differentiation of activated satellite cells. In striking contrast, satellite cells in p38-α–null mice display increased expression of Pax7, augmented proliferation, and defective differentiation (Perdiguero et al., 2007), which is the inverse phenotype of p38-γ deficiency. Thus, the present study by Gillespie et al. (2009), together with other prior studies, highlights the surprisingly distinct role for differing members of the p38 MAPK family in either promoting or inhibiting the differentiation of activated satellite cells. It seems likely that the balance between p38-α and p38-γ MAPK activity in activated satellite cells serves as an accelerator or brake, respectively, to drive the process of skeletal muscle differentiation. Together, they resemble the conflicting interests of the two-headed pushmi-pullyu, who struggles to go in two opposite directions simultaneously (Fig. 1; Lofting, 1920). Although the activity of the pro-differentiation signal p38-α MAPK is known to be regulated during skeletal muscle differentiation by the cell surface Ig superfamily member Cdo (Takaesu et al., 2006), the signals that specifically regulate p38-γ MAPK activity in proliferating myoblasts or differentiated myocytes are unknown. Lastly, it seems likely that p38 MAPK family members play an additional important role during satellite cell activation, as treatment of quiescent satellite cells with SB203580, a p38-α/β MAPK inhibitor, blocks both the proliferation and induction of MyoD in such cells (Jones et al., 2005), and thus suggests that this kinase family also plays an important role in regulating entry of quiescent satellite cells to become a transient amplifying population.
Figure 1.

What's an activated satellite cell to do? Although p38-α MAPK activity simultaneously promotes the differentiation of activated satellite cells and inhibits their proliferation, p38-γ MAPK activity works in an opposing fashion to block differentiation of these cells, and instead promotes their proliferation. Thus, the conflicting signals of p38-α versus p38-γ MAPK activity in activated satellite cells resemble the conflicting interests of the two headed pushmi-pullyu, who struggles to go in two opposite directions simultaneously (Lofting, 1920).

What's an activated satellite cell to do? Although p38-α MAPK activity simultaneously promotes the differentiation of activated satellite cells and inhibits their proliferation, p38-γ MAPK activity works in an opposing fashion to block differentiation of these cells, and instead promotes their proliferation. Thus, the conflicting signals of p38-α versus p38-γ MAPK activity in activated satellite cells resemble the conflicting interests of the two headed pushmi-pullyu, who struggles to go in two opposite directions simultaneously (Lofting, 1920).
  25 in total

1.  Pax7 is required for the specification of myogenic satellite cells.

Authors:  P Seale; L A Sabourin; A Girgis-Gabardo; A Mansouri; P Gruss; M A Rudnicki
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

2.  Pbx marks genes for activation by MyoD indicating a role for a homeodomain protein in establishing myogenic potential.

Authors:  Charlotte A Berkes; Donald A Bergstrom; Bennett H Penn; Karen J Seaver; Paul S Knoepfler; Stephen J Tapscott
Journal:  Mol Cell       Date:  2004-05-21       Impact factor: 17.970

Review 3.  The skeletal muscle satellite cell: the stem cell that came in from the cold.

Authors:  Peter S Zammit; Terence A Partridge; Zipora Yablonka-Reuveni
Journal:  J Histochem Cytochem       Date:  2006-08-09       Impact factor: 2.479

4.  Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation.

Authors:  Eusebio Perdiguero; Vanessa Ruiz-Bonilla; Lionel Gresh; Lijian Hui; Esteban Ballestar; Pedro Sousa-Victor; Bernat Baeza-Raja; Mercè Jardí; Anna Bosch-Comas; Manel Esteller; Carme Caelles; Antonio L Serrano; Erwin F Wagner; Pura Muñoz-Cánoves
Journal:  EMBO J       Date:  2007-02-15       Impact factor: 11.598

5.  MyoD is functionally linked to the silencing of a muscle-specific regulatory gene prior to skeletal myogenesis.

Authors:  Asoke Mal; Marian L Harter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-10       Impact factor: 11.205

6.  p38-{gamma}-dependent gene silencing restricts entry into the myogenic differentiation program.

Authors:  Mark A Gillespie; Fabien Le Grand; Anthony Scimè; Shihuan Kuang; Julia von Maltzahn; Vanessa Seale; Ana Cuenda; Jeffrey A Ranish; Michael A Rudnicki
Journal:  J Cell Biol       Date:  2009-12-21       Impact factor: 10.539

7.  Efficient adult skeletal muscle regeneration in mice deficient in p38beta, p38gamma and p38delta MAP kinases.

Authors:  Vanessa Ruiz-Bonilla; Eusebio Perdiguero; Lionel Gresh; Antonio L Serrano; Mònica Zamora; Pedro Sousa-Victor; Mercè Jardí; Erwin F Wagner; Pura Muñoz-Cánoves
Journal:  Cell Cycle       Date:  2008-05-12       Impact factor: 4.534

Review 8.  The Heterochromatin Protein 1 family.

Authors:  Gwen Lomberk; Lori Wallrath; Raul Urrutia
Journal:  Genome Biol       Date:  2006       Impact factor: 13.583

9.  p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci.

Authors:  Cristiano Simone; Sonia Vanina Forcales; David A Hill; Anthony N Imbalzano; Lucia Latella; Pier Lorenzo Puri
Journal:  Nat Genet       Date:  2004-06-20       Impact factor: 38.330

10.  Activation of p38alpha/beta MAPK in myogenesis via binding of the scaffold protein JLP to the cell surface protein Cdo.

Authors:  Giichi Takaesu; Jong-Sun Kang; Gyu-Un Bae; Min-Jeong Yi; Clement M Lee; E Premkumar Reddy; Robert S Krauss
Journal:  J Cell Biol       Date:  2006-10-30       Impact factor: 10.539

View more
  9 in total

1.  p38γ Mitogen-activated protein kinase signals through phosphorylating its phosphatase PTPH1 in regulating ras protein oncogenesis and stress response.

Authors:  Songwang Hou; Padmanaban S Suresh; Xiaomei Qi; Adrienne Lepp; Shama P Mirza; Guan Chen
Journal:  J Biol Chem       Date:  2012-06-22       Impact factor: 5.157

2.  p38γ mitogen-activated protein kinase (MAPK) confers breast cancer hormone sensitivity by switching estrogen receptor (ER) signaling from classical to nonclassical pathway via stimulating ER phosphorylation and c-Jun transcription.

Authors:  Xiaomei Qi; Huiying Zhi; Adrienne Lepp; Phillip Wang; Jian Huang; Zainab Basir; Christopher R Chitambar; Charles R Myers; Guan Chen
Journal:  J Biol Chem       Date:  2012-03-07       Impact factor: 5.157

3.  Separating myoblast differentiation from muscle cell fusion using IGF-I and the p38 MAP kinase inhibitor SB202190.

Authors:  Samantha Gardner; Sean M Gross; Larry L David; John E Klimek; Peter Rotwein
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-05       Impact factor: 4.249

4.  TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration.

Authors:  Daniela Palacios; Chiara Mozzetta; Silvia Consalvi; Giuseppina Caretti; Valentina Saccone; Valentina Proserpio; Victor E Marquez; Sergio Valente; Antonello Mai; Sonia V Forcales; Vittorio Sartorelli; Pier Lorenzo Puri
Journal:  Cell Stem Cell       Date:  2010-10-08       Impact factor: 24.633

Review 5.  Chromatin signaling in muscle stem cells: interpreting the regenerative microenvironment.

Authors:  Arianna Brancaccio; Daniela Palacios
Journal:  Front Aging Neurosci       Date:  2015-04-07       Impact factor: 5.750

6.  Canadine from Corydalis turtschaninovii Stimulates Myoblast Differentiation and Protects against Myotube Atrophy.

Authors:  Heyjin Lee; Sang-Jin Lee; Gyu-Un Bae; Nam-In Baek; Jae-Ha Ryu
Journal:  Int J Mol Sci       Date:  2017-12-18       Impact factor: 5.923

7.  Bioactive biodegradable polycitrate nanoclusters enhances the myoblast differentiation and in vivo skeletal muscle regeneration via p38 MAPK signaling pathway.

Authors:  Yi Guo; Min Wang; Juan Ge; Wen Niu; Mi Chen; Wei Cheng; Bo Lei
Journal:  Bioact Mater       Date:  2020-04-15

8.  A Chalcone from Ashitaba (Angelica keiskei) Stimulates Myoblast Differentiation and Inhibits Dexamethasone-Induced Muscle Atrophy.

Authors:  Minson Kweon; Hyejin Lee; Cheol Park; Yung Hyun Choi; Jae-Ha Ryu
Journal:  Nutrients       Date:  2019-10-10       Impact factor: 5.717

9.  Z-ajoene from Crushed Garlic Alleviates Cancer-Induced Skeletal Muscle Atrophy.

Authors:  Hyejin Lee; Ji-Won Heo; A-Reum Kim; Minson Kweon; Sorim Nam; Jong-Seok Lim; Mi-Kyung Sung; Sung-Eun Kim; Jae-Ha Ryu
Journal:  Nutrients       Date:  2019-11-10       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.